277 related articles for article (PubMed ID: 18242381)
1. Economic impact of tumor markers in bladder cancer surveillance.
Hong YM; Loughlin KR
Urology; 2008 Jan; 71(1):131-5. PubMed ID: 18242381
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.
Lotan Y; Roehrborn CG
J Urol; 2002 Jan; 167(1):75-9. PubMed ID: 11743279
[TBL] [Abstract][Full Text] [Related]
3. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.
Lotan Y; Svatek RS; Sagalowsky AI
Cancer; 2006 Sep; 107(5):982-90. PubMed ID: 16862567
[TBL] [Abstract][Full Text] [Related]
4. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
de Bekker-Grob EW; van der Aa MN; Zwarthoff EC; Eijkemans MJ; van Rhijn BW; van der Kwast TH; Steyerberg EW
BJU Int; 2009 Jul; 104(1):41-7. PubMed ID: 19500328
[TBL] [Abstract][Full Text] [Related]
5. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
6. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis.
Nam RK; Redelmeier DA; Spiess PE; Sampson HA; Fradet Y; Jewett MA
J Urol; 2000 Mar; 163(3):752-7. PubMed ID: 10687970
[TBL] [Abstract][Full Text] [Related]
7. Urothelial cancer biomarkers for detection and surveillance.
Liou LS
Urology; 2006 Mar; 67(3 Suppl 1):25-33; discussion 33-4. PubMed ID: 16530072
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.
Svatek RS; Sagalowsky AI; Lotan Y
Urol Oncol; 2006; 24(4):338-43. PubMed ID: 16818188
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of NMP22 in the management of bladder cancer.
Lachaine J; Valiquette L; Crott R
Can J Urol; 2000 Apr; 7(2):974-80. PubMed ID: 11119441
[TBL] [Abstract][Full Text] [Related]
10. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies.
van Kessel KE; Kompier LC; de Bekker-Grob EW; Zuiverloon TC; Vergouwe Y; Zwarthoff EC; Steyerberg EW
J Urol; 2013 May; 189(5):1676-81. PubMed ID: 23142690
[TBL] [Abstract][Full Text] [Related]
11. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.
Lokeshwar VB; Habuchi T; Grossman HB; Murphy WM; Hautmann SH; Hemstreet GP; Bono AV; Getzenberg RH; Goebell P; Schmitz-Dräger BJ; Schalken JA; Fradet Y; Marberger M; Messing E; Droller MJ
Urology; 2005 Dec; 66(6 Suppl 1):35-63. PubMed ID: 16399415
[TBL] [Abstract][Full Text] [Related]
12. [New diagnostic tests for urothelial tumors of the bladder].
Irani J
Prog Urol; 1998 Sep; 8(4):481-6. PubMed ID: 9834508
[TBL] [Abstract][Full Text] [Related]
13. Potential of urinary biomarkers in early bladder cancer diagnosis.
Lam T; Nabi G
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1105-15. PubMed ID: 18028019
[TBL] [Abstract][Full Text] [Related]
14. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
[TBL] [Abstract][Full Text] [Related]
15. Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer.
Lintula S; Hotakainen K
Expert Opin Biol Ther; 2010 Aug; 10(8):1169-80. PubMed ID: 20446896
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer.
Black PC; Brown GA; Dinney CP
J Clin Oncol; 2006 Dec; 24(35):5528-35. PubMed ID: 17158538
[TBL] [Abstract][Full Text] [Related]
18. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives.
Yossepowitch O; Herr HW; Donat SM
J Urol; 2007 Apr; 177(4):1277-82; discussion 1282. PubMed ID: 17382711
[TBL] [Abstract][Full Text] [Related]
19. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.
Kamat AM; Karam JA; Grossman HB; Kader AK; Munsell M; Dinney CP
BJU Int; 2011 Oct; 108(7):1119-23. PubMed ID: 21426474
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
